We found that targeting HEATR1 decreases GBM and GSC proliferation as measured by immunostaining with the cell cycle marker Ki67 and S-phase labelling via 5-ethynyl-2’-deoxyuridine (EdU) incorporation (Fig. 3A–L). This evidence concerns the gene HEATR1 and glioblastoma.